These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36741853)

  • 1. Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study.
    Lee W; Kang J; Park JB; Seo WW; Lee SY; Lim WH; Jeon KH; Hwang IC; Kim HL
    Health Sci Rep; 2023 Feb; 6(2):e1056. PubMed ID: 36741853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction.
    Kim J; Kang D; Kim SE; Park H; Park TK; Lee JM; Yang JH; Song YB; Choi JH; Choi SH; Gwon HC; Guallar E; Cho J; Hahn JY
    J Korean Med Sci; 2023 Jun; 38(25):e202. PubMed ID: 37365730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
    ARB Trialists Collaboration
    J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension.
    Akioyamen L; Levine M; Sherifali D; O'Reilly D; Frankfurter C; Pullenayegum E; Goeree R; Tsoi B
    J Am Soc Hypertens; 2016 Jan; 10(1):55-69.e1. PubMed ID: 26684588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
    Yoo YG; Lim MJ; Kim JS; Jeong HE; Ko H; Shin JY
    Medicine (Baltimore); 2023 Nov; 102(46):e36098. PubMed ID: 37986329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
    Antoniou T; Camacho X; Yao Z; Gomes T; Juurlink DN; Mamdani MM
    CMAJ; 2013 Sep; 185(12):1035-41. PubMed ID: 23836857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
    Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
    J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
    Nixon RM; Müller E; Lowy A; Falvey H
    Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
    Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.
    Zhang Z; Yang H; Guo H
    Int J Clin Pharm; 2024 Jun; ():. PubMed ID: 38861046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
    Zaiken K; Hudd TR; Cheng JW
    Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
    Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
    Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC; Heran BS; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.